Outlook Therapeutics, Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

Outlook Therapeutics, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 Outlook Therapeutics Announces Resubmission of Biologics License Application to U. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) ISELIN, N.